

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the National Medical Products Administration of China (the “NMPA”) has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group’s Metoprolol Tartrate Injection (5ml), which is the third of such approval for the PRC entities. Metoprolol Tartrate Injection is mainly used in the treatment of tachycardia (abnormally fast heart rate), and in the prevention and treatment of tachycardia and chest pain after acute myocardial infarction.

From October this year to the date of this announcement, the Group has obtained approvals from the NMPA for preparation products with a total of 7 types with 8 specifications, for 1 bulk pharmaceutical product, and for drug clinical trials with a total of 2 types with 4 specifications.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 30 October 2023

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.